This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I49.82 (Long QT syndrome) | Special Copayment Reduction: V296 (rare disease) |
| B. Synonyms | Not applicable |
| C. Adult onset | Likelihood of first onset in adulthood moderate — congenital long QT syndrome often presents in childhood or adolescence with syncope or sudden death, but in certain subtypes such as LQT2 (KCNH2 variants) and LQT5, and in women, first presentation in adulthood (especially within a few months after childbirth) is considerable. In addition, acquired (drug-induced, electrolyte abnormality) long QT syndrome occurs in adults of all ages. |
| 1. History | 1957 Jervell and Lange-Nielsen reported QT prolongation with congenital deafness → 1963 Romano and Ward described the autosomal dominant form → 1991 first linkage of an LQTS gene (KCNQ1) → 1995~96 cloning of the major causative genes. |
| 2. Causes | Congenital: mutations in ion channel genes (KCNQ1, KCNH2, SCN5A, etc.). Acquired: QT-prolonging drugs, electrolyte abnormalities (hypokalemia, hypomagnesemia), bradycardia, myocardial ischemia. |
| 3. Genetics | More than 15 genes reported. LQT1 (KCNQ1, 35%), LQT2 (KCNH2, 30%), and LQT3 (SCN5A, 10%) account for about 75% of the total. Autosomal dominant (Romano-Ward) and recessive (Jervell-Lange-Nielsen) subtypes. |
| 4. General epidemiology | Prevalence of congenital LQTS 1/2,000. A major cause of sudden death in children and unexplained syncope. Symptom presentation more common in women. |
| 5. Pathophysiology | Delayed ventricular repolarization → QTc prolongation → formation of early afterdepolarizations (EAD) → Torsades de Pointes (TdP) → ventricular fibrillation → sudden death. |
| 6. Symptoms | Syncope (most common), presyncope, palpitations, seizures (mistaken for epilepsy). Sudden death may be the first presentation. LQT1 with exercise, LQT2 with auditory stimuli, LQT3 during sleep. |
| 7. Signs | QTc prolongation on ECG (women ≥480 ms, men ≥470 ms), T-wave abnormalities (notched T waves, bifid T waves, broad T waves). Congenital deafness in Jervell-Lange-Nielsen. |
| 8. Screening | ECG QTc measurement in first-degree relatives with a family history. Targeted gene testing when a gene is identified. QTc measurement before prescribing drugs. |
| 9. Diagnosis | 12-lead ECG (QTc measurement, T-wave morphology). Schwartz score. Gene panel testing. Exercise stress test (aid to LQT1 diagnosis). |
| 10. Treatment | Beta-blockers (first-line, especially effective for LQT1 and LQT2). Avoidance of QT-prolonging drugs. ICD (high-risk groups). Left cardiac sympathetic denervation (LCSD). Mexiletine (LQT3). |
| 11. Prognosis | Annual sudden death risk < 0.5% with beta-blocker treatment. LQT3 relatively poor. Favorable prognosis in women after treatment. Beta-blocker-refractory high-risk groups supplemented with ICD. |
| 12. Prevention | Management of QT-prolonging drug lists (CredibleMeds), electrolyte correction, restriction of strenuous exercise, genetic counseling and family screening. |
| 13. References | Schwartz PJ, et al. Long QT syndrome. Circ Arrhythm Electrophysiol. 2012 … and 9 other papers |
The historical description of Long QT Syndrome (LQTS) begins in 1957 with Anton Jervell and Fred Lange-Nielsen of Norway. They reported a family in which four siblings with congenital deafness had marked prolongation of the ECG QT interval, recurrent syncope, and sudden death. This familial syndrome was later named Jervell-Lange-Nielsen syndrome (JLNS) and is the most severe form of congenital LQTS, transmitted by autosomal recessive inheritance.
In 1963, Romano of Italy and Ward of Ireland each independently described a familial syndrome with QT prolongation and syncope without deafness. This was named Romano-Ward syndrome (RWS), with autosomal dominant inheritance, and is the most common form of congenital LQTS. In 1964, Dessertenne named the distinctive polymorphic ventricular tachycardia occurring in the setting of QT prolongation "Torsades de Pointes (TdP)." It was later clearly confirmed that this arrhythmia is the direct cause of syncope and sudden death.
In 1985, Schwartz et al. introduced the "Schwartz diagnostic score," which scores clinical symptoms, QTc values, and family history, systematizing the clinical diagnostic criteria. In 1991, Keating et al. first mapped an RWS gene to chromosome 11 (11p15.5) by linkage analysis, and in 1995~1996 the major causative genes, including KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3), were cloned one after another. Thereafter, genotype classification based on molecular genetics became the standard for diagnosis and treatment of LQTS.
In the 2000s, more than 15 LQTS-related genes were reported, and understanding of patients with genotype-negative LQTS (genetic-negative LQTS) also improved. Since 2015, the long-term efficacy of left cardiac sympathetic denervation (LCSD) has been demonstrated in large cohorts, establishing it as an alternative or complement to ICD in beta-blocker-refractory patients. Currently, genome-wide association studies (GWAS) have identified numerous polymorphic variants affecting QTc, contributing to understanding of genetic susceptibility to acquired LQTS.
Long QT syndrome is broadly divided into congenital (inherited) and acquired forms. In both forms, the QTc interval is prolonged due to delayed ventricular repolarization, and they share the risk of syncope and sudden death due to Torsades de Pointes (TdP) and ventricular fibrillation.
Congenital long QT syndrome: caused by pathogenic variants in genes encoding cardiac ion channels or ion channel-related proteins. More than 15 causative genes have been reported to date, but most cases are due to variants in three genes: KCNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3). LQT1: KCNQ1 gene variants → reduced slow delayed rectifier potassium current (IKs). LQT2: KCNH2 gene variants → reduced rapid delayed rectifier potassium current (IKr). LQT3: SCN5A gene variants → persistent increase in sodium current (INa) (gain-of-function). Rare subtypes include KCNE1 (LQT5), KCNE2 (LQT6), KCNJ2 (LQT7, Andersen-Tawil syndrome), and CACNA1C (LQT8, Timothy syndrome).
Acquired (drug-induced) long QT syndrome: drugs that prolong the QT interval are the most common cause. Hundreds of drugs carry a risk of QTc prolongation and TdP, including antiarrhythmics (sotalol, amiodarone, dofetilide), antibiotics (azithromycin, fluoroquinolones), antifungals (fluconazole), antihistamines (older terfenadine), antipsychotics (haloperidol, ziprasidone), antidepressants (tricyclic antidepressants), and anticancer drugs (aromatase inhibitors, VEGF inhibitors). The CredibleMeds (AzCERT) database is the standard reference for drug-specific TdP risk classification.
Other acquired causes: electrolyte abnormalities such as hypokalemia, hypomagnesemia, and hypocalcemia. Severe bradycardia (complete atrioventricular block, sick sinus syndrome). Myocardial ischemia and infarction. Stroke and cerebral hemorrhage (autonomic imbalance). Severe nutritional deficiency (anorexia nervosa). When drugs or electrolyte abnormalities are superimposed on a genetic predisposition (carriers of latent congenital LQTS variants), the risk of QTc prolongation rises markedly.
There are two main inheritance patterns of congenital long QT syndrome. Romano-Ward syndrome is autosomal dominant and the most common form (affected parent → 50% of children), with normal hearing. Most subtypes, including LQT1 (KCNQ1), LQT2 (KCNH2), and LQT3 (SCN5A), belong to it. Jervell-Lange-Nielsen syndrome is autosomal recessive, due to homozygous or compound heterozygous variants in KCNQ1 (JLN1) or KCNE1 (JLN2), and is accompanied by congenital sensorineural deafness and very severe QT prolongation.
LQT1 (KCNQ1 gene, 11p15.5): encodes the alpha subunit of the IKs channel. Accounts for about 35% of all LQTS. Cardiac events occur with exercise (especially swimming) or sympathetic activation. LQT2 (KCNH2 gene, 7q35-q36): encodes the alpha subunit of the IKr channel. About 30%. Occur with auditory stimuli (sudden loud noises, alarms) or emotional stimuli. Increased risk within a few months postpartum. LQT3 (SCN5A gene, 3p21): Nav1.5 sodium channel. About 10%. Occur at night or at rest, with relatively severe clinical outcomes. LQT7 (KCNJ2, Andersen-Tawil): potassium channel abnormality, accompanied by periodic paralysis and facial and skeletal abnormalities. LQT8 (CACNA1C, Timothy syndrome): L-type calcium channel, accompanied by syndactyly, autism, and immunodeficiency. The current diagnostic yield of LQTS genetic testing is 75~80% (genotype-positive LQTS), and in the remaining about 20~25% no variant is identified (genotype-negative LQTS).
The prevalence of congenital long QT syndrome is estimated at about 1 in 2,000 births, making it the most common inherited cardiac channelopathy. The actual population prevalence may be higher, because patients who are asymptomatic or have only mild QTc prolongation go undiagnosed. Worldwide, about 3~4 million people are estimated to be affected.
Congenital LQTS occurs in both sexes, but clinical symptoms (syncope, sudden death) appear more commonly in women. This is related to women having a longer baseline QTc than men (estrogen inhibits IKr) and to the tendency for risk to increase within a few months postpartum, especially in LQT2 patients. After adolescence, the incidence of cardiac events in untreated women (without beta-blockers) is higher than in men. In contrast, in childhood (before age 10), symptom presentation is more common in boys.
Epidemiology by genotype: LQT1 accounts for about 35%, LQT2 about 30%, LQT3 about 10%, the remaining subtypes about 5%, and genotype-negative about 20%. JLNS is very rare, with a prevalence of 1/100,000~200,000. In Korea, LQTS is registered as a rare disease eligible for Special Copayment Reduction (V296). Systematic data on the domestic incidence are lacking, but it is estimated to be at a level similar to Western countries. Differentiating LQTS is important in children with unexplained sudden death or patients with recurrent syncope.
The core pathophysiology of long QT syndrome is prolongation of the action potential duration (APD) of ventricular myocytes. In normal ventricular myocytes, the action potential proceeds in the order of depolarization (phase 0, sodium current influx), early repolarization (phase 1, potassium current), plateau (phase 2, balance between calcium current influx and potassium current), and late repolarization (phase 3, rapid repolarization by the potassium currents IKr and IKs).
In LQTS, APD is prolonged when phase 3 repolarization is delayed due to reduced IKr (LQT2) or IKs (LQT1), or when depolarizing current persists into phases 2~3 due to a persistent increase in INa (LQT3). This appears on the ECG as prolongation of the QT interval (QTc). During the prolonged APD, early afterdepolarizations (EAD) form as L-type calcium channels reactivate before repolarization has sufficiently progressed. EADs trigger premature ventricular contractions (PVC), and when these PVCs stimulate myocardium in a vulnerable repolarization state, reentrant circuits based on transmural dispersion of repolarization (TDR) form. This progresses to Torsades de Pointes (TdP), and when TdP degenerates into ventricular fibrillation, syncope or sudden death occurs.
Differences in triggering mechanisms by genotype are important. In LQT1, IKs must increase markedly with sympathetic stimulation (increased cAMP upon β-adrenergic receptor activation) to shorten APD; when this response is absent because of KCNQ1 variants, APD does not shorten despite the rise in heart rate during exercise, increasing risk. In LQT2, reduced IKr is aggravated by hypokalemia, drugs, and auditory stimuli, and QTc prolongation becomes more severe especially in the postpartum period. In LQT3, persistent INa is more prominent during bradycardia (slow heart rate), increasing risk at night and during sleep.
The clinical symptoms of long QT syndrome are mainly caused by impaired cerebral blood flow due to episodes of TdP and ventricular fibrillation.
Syncope: the most common symptom, occurring in about 50~70% of LQTS patients. It typically occurs abruptly in genotype-specific triggering situations such as exercise (LQT1), auditory and emotional stimuli (LQT2), and sleep (LQT3). Palpitations and dizziness sometimes precede syncope, but sudden loss of consciousness without prodromal symptoms is also common. It is often mistaken for epileptic seizures, so when convulsions accompany recurrent syncope, LQTS must be differentiated.
Presyncope and palpitations: when episodes of ventricular tachycardia terminate quickly, patients experience only a near-syncopal state (dizziness, momentary darkening of vision) or palpitations and recover. These symptoms may recur and at some point progress to syncope or sudden death, so caution is needed.
Sudden cardiac death: especially in young age groups (children, adolescents, young adults), sudden death without warning symptoms can be the first presentation. In untreated LQTS patients (genetically confirmed, symptomatic), the annual risk of sudden death is estimated at about 0.3~0.9%, but it is higher in high-risk groups. Patterns triggered during swimming, during exercise, or by sudden loud noises (alarm clocks) differ by genotype.
Deafness (JLNS): in JLNS, congenital sensorineural deafness (bilateral sensorineural hearing loss) accompanies the cardiac symptoms. Because the parents may be carriers with normal hearing, ECG testing is recommended in children with hearing impairment.
Asymptomatic QTc prolongation: there are also many cases in which patients carry a gene variant but QTc remains in the borderline range (450~470 ms) with no cardiac events. In these patients, administration of QT-prolonging drugs, hypokalemia, and strenuous exercise can be triggers for symptoms.
The most important clinical sign of long QT syndrome is QTc prolongation on the ECG.
QTc measurement: QTc = QT / √RR (Bazett formula). Diagnostic criteria QTc: ≥500 ms (markedly abnormal in both sexes), ≥480 ms (abnormal in women), ≥470 ms (abnormal in men). The 2022 ESC guidelines define QTc ≥460 ms as abnormal in genotype-positive patients. QTc is measured in lead V5 or as the average of several leads. Because correction errors of the Bazett formula can occur with bradycardia or tachycardia, measurement at a heart rate of 60~90 bpm is ideal.
T-wave morphology abnormalities: there are characteristic T-wave patterns by LQTS genotype. LQT1: broad, flat T wave (broad-based T wave). LQT2: notched, bifid T wave (bifid T wave, notched T wave). LQT3: narrow, late-onset tall T wave (tall, late-onset T wave). T-wave morphology helps predict genotype, but genetic testing is needed for confirmation.
Schwartz diagnostic score (2011 revision): QTc ≥480 ms (3 points), 470~479 ms (2 points), 460~469 ms (1 point); history of TdP (2 points); T-wave alternans (1 point); notched T waves in 3 or more leads (1 point); resting heart rate below the sex-specific reference (0.5 points); unexplained syncope—unrelated to stress (1 point), related to stress (2 points); congenital deafness (0.5 points); family history (family member with confirmed LQTS 0.5 points, sudden death before age 40 0.5 points). Total score ≥3.5 high probability, 1.5~3.0 intermediate, ≤1.0 low.
Holter ECG and exercise stress test: on 24-hour Holter monitoring, maximum QTc, QTc variability, and TdP or PVC patterns are evaluated. On exercise stress testing, insufficient shortening of QTc in the recovery phase (within 4 minutes after exercise) (LQT1) or a recovery-phase QTc ≥ 445 ms suggests LQTS.
General newborn screening for long QT syndrome is performed in some countries (Italy) but has not become universal.
Family screening: first-degree relatives (parents, siblings, children) of patients with confirmed LQTS have QTc measured by 12-lead ECG, and when a pathogenic variant has been identified in the family, targeted genetic testing is performed. Family members with negative genetic testing and normal QTc are unlikely to have LQTS, but some may carry a gene variant without a clinical phenotype (symptoms, QTc abnormality).
QTc screening before drug prescription: before administering drugs with a high risk of QT prolongation (Class IA and III antiarrhythmics, some antibiotics, antipsychotics, etc.), baseline QTc is measured and risk factors such as hypokalemia and hypomagnesemia are corrected. QTc is remeasured within 24~48 hours after administration, and discontinuation or change of the drug is considered if QTc is ≥500 ms or has increased by 60 ms or more from baseline.
Screening of athletes and sports participants: including an ECG in pre-participation screening of competitive athletes allows early detection of LQTS. Athletes with QTc abnormalities or symptoms (syncope, palpitations, sudden death in the family) need immediate specialist cardiac evaluation.
The diagnosis of long QT syndrome is made by integrating 12-lead ECG QTc measurement, the Schwartz score, genetic testing, and exercise stress testing.
12-lead ECG: the key to diagnosis. QTc is measured repeatedly on several resting ECGs (repeated measurement is recommended over a single measurement because of variability). QTc ≥480 ms (women) or ≥470 ms (men) strongly suggests LQTS. In patients with borderline QTc (440~470 ms), T-wave morphology analysis, the Schwartz score, and genetic testing complement the diagnosis.
Genetic testing: when LQTS is clinically suspected or diagnosed, NGS of an LQTS-related gene panel (including at least KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, KCNJ2, CACNA1C) is recommended. A positive genetic test (identification of a pathogenic or likely pathogenic variant) is confirmatory and is essential for family screening and genotype-specific treatment planning. Even with a negative genetic test (VUS or negative), the diagnosis of LQTS stands if clinical criteria are met.
Exercise stress test: evaluates whether QTc is prolonged in the recovery phase. Particularly useful as an aid to diagnosing LQT1. Whether VT/VF or syncope is reproduced during exercise is also evaluated. Because of the risk of provoking arrhythmia, it is performed at specialized facilities.
Epinephrine provocation test: a test evaluating QTc changes after low-dose intravenous epinephrine, used as an aid to diagnosing LQT1 (in LQT1, QTc paradoxically prolongs with epinephrine stimulation). It is performed only at specialized centers and applied cautiously because of the risk of provoking ventricular arrhythmias.
Treatment of long QT syndrome consists of avoidance of triggering factors, drug treatment, and procedural/surgical treatment. Differentiating treatment strategies by genotype is important.
Beta-blockers (first-line treatment): beta-blockers are the first-line treatment in almost all LQTS patients. Nadolol has the longest-standing evidence, and propranolol is also used. There are reports that atenolol is somewhat less effective than nadolol in LQT1. Beta-blockers are most effective in LQT1 (compensating for reduced IKs by sympathetic inhibition) and are also effective in LQT2. In LQT3, efficacy is relatively low. In patients with a history of syncope, the risk of recurrent cardiac events decreases by about 50~70% after beta-blocker administration.
Avoidance of QT-prolonging drugs and triggering factors: in all LQTS patients (including genotype-positive and genotype-negative clinically diagnosed patients), the list of QT-prolonging drugs (CredibleMeds classification) is checked and use of high-risk drugs is avoided. Hypokalemia and hypomagnesemia are prevented, and electrolytes are actively corrected during vomiting or diarrhea. In LQT1, participation in strenuous competitive sports (especially swimming) is restricted. In LQT2, avoidance of auditory stimuli (alarm clocks, sudden loud noises) and minimizing phone sounds during sleep are recommended.
Implantable cardioverter-defibrillator (ICD): ICD implantation is recommended when syncope or cardiac arrest occurs despite beta-blocker treatment, when there is a history of resuscitation from sudden death, and in high-risk groups with low beta-blocker response such as LQT3. The ICD detects and defibrillates TdP/VF to prevent sudden death. Because of lead-related complications in children, the subcutaneous ICD (S-ICD) is used as an alternative.
Left cardiac sympathetic denervation (LCSD): a treatment that surgically removes the left sympathetic ganglia (T1~T4) to reduce sympathetic tone to the heart. It is an alternative when patients are refractory to or have adverse effects from beta-blockers and ICD implantation is difficult or not desired. It is particularly effective in LQT1 and LQT2, reducing cardiac events by 80~90% in studies. It is performed by thoracoscopic surgery and is relatively minimally invasive.
Genotype-specific treatment: in LQT3, mexiletine (a sodium channel blocker) suppresses the persistent increase in INa, shortening QTc and reducing cardiac events. In LQT2, quinidine has been reported to be partly effective in compensating for reduced IKr, but there are problems with adverse effects.
The prognosis of long QT syndrome varies greatly depending on genotype, severity (QTc value), presence of symptoms, and response to treatment.
Prognosis with beta-blocker treatment: in LQTS patients receiving appropriate beta-blocker treatment, the annual risk of sudden death decreases to less than 0.3~0.5%. In untreated symptomatic LQTS patients, the annual incidence of cardiac events (syncope + sudden death) is estimated at about 5~7%. LQT1 and LQT2 respond well to beta-blockers and have a relatively favorable prognosis. LQT3 has a low beta-blocker response, and cardiac events occur mainly during bradycardia, so the prognosis is relatively poor.
Sex and prognosis: before treatment, the incidence of cardiac events is higher in women than in men, but after beta-blocker treatment, women tend to show a better prognosis than men. In particular, the postpartum period (within 9 months after childbirth) is a high-risk period for women with LQT, and beta-blockers should be continued during this period.
QTc and prognosis: patients with QTc ≥500 ms have about twice the risk of cardiac events of patients with QTc < 500 ms. JLNS (JLN1, JLN2) is the most severe subtype, with very long QTc and serious cardiac events occurring in childhood. In asymptomatic genotype-positive patients with QTc of 440~460 ms, the annual risk of sudden death is very low (less than 0.03%). However, because the risk can rise sharply in these patients when exposed to QT-prolonging drugs or hypokalemia, education is important.
Prevention of long QT syndrome focuses on minimizing triggering factors in genetically susceptible patients and preventing fatal arrhythmias through early diagnosis and treatment.
Management of QT-prolonging drugs: all LQTS patients and their families (including genotype-positive members) should check the QTc-prolonging risk of prescribed drugs through the CredibleMeds (www.crediblemeds.org) database. High-risk drugs (sotalol, dofetilide, azithromycin, fluoroquinolones, haloperidol, etc.) should be avoided as much as possible in LQTS patients and, when unavoidable, administered under inpatient monitoring. Wearing a Medical Alert bracelet and informing every physician of the LQTS diagnosis are important.
Electrolyte correction and maintenance: because hypokalemia and hypomagnesemia markedly prolong QTc, electrolytes should be actively replenished during vomiting, diarrhea, or excessive sweating. A high-potassium diet, potassium supplements if needed, and magnesium supplementation are recommended. Caution is needed when using diuretics (especially loop diuretics and potassium-wasting diuretics).
Genetic counseling and family screening: families of patients with confirmed LQTS should receive genetic counseling, and all first-degree relatives should undergo ECG QTc measurement and genetic testing (targeted variant analysis). In women with LQTS planning pregnancy, a management plan for pregnancy and the postpartum period should be established in advance, and education about the high-risk postpartum period is particularly important in women with LQT2. Selection of affected embryos through preimplantation genetic testing (PGT) is also considered in some families.
Activity and lifestyle guidance: patients with LQT1 avoid competitive sports (especially swimming), and with individualized exercise intensity, low- to moderate-intensity exercise is acceptable. Patients with LQT2 minimize auditory stimuli (alarm clocks on vibration mode, reduced phone ringer volume). Living in an environment with access to an automated external defibrillator (AED) and having family members trained in cardiopulmonary resuscitation (CPR) are recommended.
Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120(18):1761-1767. DOI: 10.1161/CIRCULATIONAHA.109.863209. PMID: 19841298.
Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes. Heart Rhythm. 2013;10(12):1932-1963. DOI: 10.1016/j.hrthm.2013.05.014. PMID: 24011539.
Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103(1):89-95. DOI: 10.1161/01.CIR.103.1.89. PMID: 11136691.
Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval, and sudden death. Am Heart J. 1957;54(1):59-68. DOI: 10.1016/0002-8703(57)90079-0. PMID: 13435203.
Moss AJ, Zareba W, Hall WJ, et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101(6):616-623. DOI: 10.1161/01.CIR.101.6.616. PMID: 10673253.
Schwartz PJ, Spazzolini C, Priori SG, et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them? Circulation. 2010;122(13):1272-1282. DOI: 10.1161/CIRCULATIONAHA.110.971622. PMID: 20837893.
Goldenberg I, Zareba W, Moss AJ. Long QT syndrome. Curr Probl Cardiol. 2008;33(11):629-694. DOI: 10.1016/j.cpcardiol.2008.07.002. PMID: 18834530.
Schwartz PJ, Ackerman MJ, Slotwiner DJ, et al. Congenital long QT syndrome from bedside to bench to bedside. Nat Rev Cardiol. 2020;17(7):388-400. DOI: 10.1038/s41569-020-0329-x. PMID: 32161964.
Bos JM, Bos KM, Johnson JN, et al. Left cardiac sympathetic denervation in long QT syndrome: analysis of therapeutic nonresponders. Circ Arrhythm Electrophysiol. 2013;6(4):705-711. DOI: 10.1161/CIRCEP.113.000382. PMID: 23868445.
Goldenberg I, Moss AJ, Peterson DR, et al. Risk factors for abrupt onset and slow termination of ventricular tachyarrhythmias in long-QT syndrome patients. Heart Rhythm. 2006;3(5):547-550. DOI: 10.1016/j.hrthm.2006.01.033. PMID: 16648062.